Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations

다국어 초록 (Multilingual Abstract)

Azacitidine is recommended for patients with higher-risk myelodysplastic syndromes (MDS) who are not eligible for intensive therapy or for patients with lower-risk MDS who have thrombocytopenia or neutropenia or have anemia that is unresponsive to other therapies. However, standard treatment with azacitidine has not been optimized and many issues about the use of azacitidine remain unresolved. The use of azacitidine is expanding rapidly, but limited comparative clinical trial data are available to (i) define the optimal use of azacitidine in patients with higher-risk MDS or around the time of allogeneic hematopoietic stem cell transplantation, (ii) identify those patients with lower-risk MDS who may benefit from treatment, and (iii) guide physicians on alternative therapies after treatment failure. Increasing evidence suggests that the clinical features, prognostic factors, and cytogenetic profiles of patients with MDS in Asia differ significantly from those of patients in Western countries, so the aim of this review is to summarize the evidence and provide practical recommendations on the use of azacitidine in patients with MDS in the Republic of Korea. Evidence considered in this review is based on published clinical data and on the clinical experience of an expert panel from the acute myeloid leukemia/MDS Working Party of the Korean Society of Hematology.

참고문헌 (Reference)

1 Bejar R, "Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes" 30 : 3376-3382, 2012

2 Malcovati L, "Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes" 25 : 3503-3510, 2007

3 Shin SH, "Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure" 48 : 678-683, 2013

4 Bosi A, "Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation" 19 : 3675-3684, 2001

5 Greenberg PL, "Revised international prognostic scoring system for myelodysplastic syndromes" 120 : 2454-2465, 2012

6 Yahng SA, "Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes" 90 : 111-120, 2013

7 Silverman LR, "Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B" 20 : 2429-2440, 2002

8 Wang XQ, "Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: a prognostic scoring system for predicting survival in RCMD" 90 : 361-369, 2009

9 Kantarjian H, "Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System" 113 : 1351-1361, 2008

10 Cazzola M, "Prognostic classification and risk assessment in myelodysplastic syndromes" 24 : 459-468, 2010

11 Gerds AT, "Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS" 18 : 1211-1218, 2012

12 Moon JH, "Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment" 89 : 681-689, 2010

13 Fenaux P, "Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion" 34 : 1410-1416, 2010

14 Uchida T, "Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes" 102 : 1680-1686, 2011

15 Kantarjian HM, "Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy" 116 : 3163-3170, 2010

16 Pollyea DA, "Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation" 40 : 1027-1032, 2007

17 Jabbour E, "Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy" 116 : 3830-3834, 2010

18 Prebet T, "Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure" 29 : 3322-3327, 2011

19 Lubbert M, "Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients" 44 : 585-588, 2009

20 Kim IH, "Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes" 36 : e146-e148, 2012

21 Garcia-Manero G, "Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management" 87 : 692-701, 2012

22 Cazzola M, "Myelodysplastic syndromes-coping with ineffective hematopoiesis" 352 : 536-538, 2005

23 Intragumtornchai T, "Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases" 22 : 453-460, 1998

24 NCCN Clinical practice guidelines in oncology, "Myelodysplastic syndromes Version 2.2013" National Comprehensive Cancer Network

25 Santini V, "Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine" 85 : 130-138, 2010

26 Jabbour E, "Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia" 115 : 1899-1905, 2009

27 Wattel E, "Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders" 98 : 983-991, 1997

28 Park MJ, "Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS" 81 : 364-373, 2008

29 Greenberg P, "International scoring system for evaluating prognosis in myelodysplastic syndromes" 89 : 2079-2088, 1997

30 Malcovati L, "Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)" 96 : 1433-1440, 2011

31 Cogle CR, "Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes" 8 : 40-46, 2010

32 Lyons RM, "Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes" 27 : 1850-1856, 2009

33 Silverman LR, "Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B" 24 : 3895-3903, 2006

34 Kim DY, "Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome" 47 : 374-379, 2012

35 De Padua Silva L, "Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome" 43 : 839-843, 2009

36 Fenaux P, "Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study" 10 : 223-232, 2009

37 Matsuda A, "Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes" 34 : 974-980, 2010

38 Lee JH, "Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome" 35 : 499-503, 2011

39 Shen L, "DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes" 28 : 605-613, 2010

40 Huong Thi Thanh Tran, "DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome" 대한의학회 26 (26): 207-213, 2011

41 Jung SW, "Cytogenetic characteristics and prognosis analysis in 231 myelodysplastic syndrome patients from a single institution" 35 : 735-740, 2011

42 Silverman LR, "Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes" 117 : 2697-2702, 2011

43 Lee JJ, "Comparisons of prognostic scoring systems for myelodysplastic syndromes: a Korean multicenter study" 23 : 425-432, 1999

44 Kim DY, "Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine" 89 : 15-23, 2010

45 Lee JH, "Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome" 92 : 889-897, 2013

46 Lee YG, "Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes" 161 : 339-347, 2013

47 Toyama K, "Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan" 7 : 499-508, 1993

48 Chen B, "Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries" 19 : 767-775, 2005

49 Dayyani F, "Cause of death in patients with lower-risk myelodysplastic syndrome" 116 : 2174-2179, 2010

50 Tintle S, "Azacitidine: a new medication associated with Sweet syndrome" 64 : e77-e79, 2011

51 Trickett HB, "Azacitidine-associated Sweet’s syndrome" 69 : 869-871, 2012

52 Gotze K, "Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group" 89 : 41-850, 2010

53 Platzbecker U, "Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial" 26 : 381-389, 2012

54 Musto P, "Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program" 116 : 1485-1494, 2010

55 Lee JH, "Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome" 17 : 305-313, 2003

56 Platzbecker U, "Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine" 18 : 1415-1421, 2012

57 Garcia-Manero G, "A prognostic score for patients with lower risk myelodysplastic syndrome" 22 : 538-543, 2008

58 Bolanos-Meade J, "5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation" 17 : 754-758, 2011

59 Field T, "5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation" 45 : 255-260, 2010

60 Smith TJ, "2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline" 24 : 3187-3205, 2006